Merial Ltd. has released what the Duluth, Ga., drug maker is calling the world’s first nonadjuvanted feline rabies vaccine with a three-year lifespan.
Other three-year rabies vaccines are made with an adjuvant that increases a cat’s immune response but that has been blamed for causing vaccine-related fibrosarcoma, a rare disease.
The new vaccine is part of the PureVax family, which includes a one-year nonadjuvanted rabies vaccine.
“The recombinant technology that has also been used to produce other vaccines such as the one-year PureVax rabies … allows the development of effective vaccines for feline viral diseases without the need for adjuvants,” said Leigh O’Mara, Ph.D., PMP, an associate director of technical marketing for Merial.
The three-year duration of immunity makes the vaccine a good choice for cat owners who don’t schedule regular veterinary checkups, Merial stated.
“Veterinarians now no longer have to choose between a multiyear adjuvanted rabies vaccine and an annual nonadjuvanted rabies vaccine for clients who do not reliably return to the clinic annually,” the company reported Monday.
PureVax Feline Rabies is recommended for healthy cats 12 weeks or older. A one-year booster vaccination is required after the initial shot.
Rabies disease occurs most often in wildlife, but the Centers for Disease Control and Prevention counted 257 feline rabies cases in 2012 in the United States compared with only 84 cases involving dogs.